StreetAlpha
13F holdings · Q3 2026

RA Capital Management

Boston, MA · files as RA Capital Management, L.P.
Know the moment RA Capital Management filesYou follow RA Capital Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1346824

RA Capital Management reported 92 stocks worth $10B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ASND (23.5%), PBLS (9.4%) and PCVX (6.5%). Compared with Q2 2026, the fund opened new positions in FRNM, AMLX and WVE, added to PBLS, TSHA and ARTV, trimmed SEPN, CLYM and ABVX and sold out of BCRX, WVE and NTLA.

Latest filing: what RA Capital Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
21 new6 added13 trimmed13 sold outBought about $1B · sold about $1.2B
New 21
See all 21 →
Added 6
See all 6 →
Trimmed 13
See all 13 →
Sold out 13
See all 13 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$10B−13.4% vs last quarter
Stocks held9221 new · 13 sold out
Top 5 weight49.3%fairly concentrated
Turnover22%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
ASND
Ascendis Pharma A/s
$2.3B23.5%10.3MNo change2 of 8
2
PBLS
Parabilis Medicines Inc Com
$942M9.4%29.2M+245K (+1%)2 of 8
3
PCVX
Vaxcyte Inc
$653M6.5%11.5MNo change8 of 8
4
RYTM
Rhythm Pharmaceuticals Inc
$635M6.4%6.7MNo change8 of 8
5
EWTX
Edgewise Therapeutics Inc
$341M3.4%8.4MNo change8 of 8
6
TYRA
Tyra Biosciences Inc
$267M2.7%12.2MNo change8 of 8
7
FRNM
Freenome Inc
$242M2.4%15.4MNew position1 of 8
8
COAG
Hemab Therapeutics Hldgs Inc
$241M2.4%7.8MNo change2 of 8
9
NAMS
Newamsterdam Pharma Company
$232M2.3%9.6MNo change8 of 8
10
SEPN
Septerna Inc
$215M2.2%5.5M−1.5M (−21%)8 of 8
🔒 82 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
BCRX
Biocryst Pharmaceuticals Inc
$158M15.8M
WVE
Wave Life Sciences Ltd
$157M27M
NUVALENT INC
$154M1.2M
NTLA
Intellia Therapeutics Inc
$76.6M4.5M
DFTX
Definium Therapeutics Inc
$70.6M1.5M

🔒 Free account: see all 13.

Reported value

last 8 quarters
$7.5BQ4 '24
$6BQ1 '25
$5.9BQ2 '25
$8.1BQ3 '25
$9.8BQ4 '25
$9.4BQ1 '26
$11.5BQ2 '26
$10BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

RA Capital Management 13F FAQ

What does RA Capital Management own?

RA Capital Management reported 92 stocks worth $10B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ASND (23.5%), PBLS (9.4%) and PCVX (6.5%). The table above lists every position in the filing (the top 10 without an account).

What did RA Capital Management buy and sell in Q3 2026?

Compared with Q2 2026: 21 new positions, 6 added to, 13 trimmed and 13 sold out. New positions include FRNM, AMLX and WVE. It sold all of BCRX, WVE and NTLA.

When will RA Capital Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is RA Capital Management's portfolio worth?

The Q3 2026 filing reports $10B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.